高级检索
中华内科杂志
期刊首页
过刊列表
高级检索
稿件发表
• 标准与讨论 •
ENGLISH ABSTRACT
中国多发性骨髓瘤诊治指南（2024年修订）
中国医师协会血液科医师分会
中华医学会血液学分会
作者及单位信息
·
DOI： 10.3760/cma.j.cn112138-20240928-00616
Guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)
Chinese Hematology Association
Chinese Society of Hematology
Huang Xiaojun
Wu Depei
Authors Info & Affiliations
Chinese Hematology Association
Chinese Society of Hematology
Huang Xiaojun
Peking University People′s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China
Wu Depei
the First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China
·
DOI： 10.3760/cma.j.cn112138-20240928-00616
9733
2176
0
3
105
33
PDF下载
APP内阅读
摘要

多发性骨髓瘤（MM）是一种克隆浆细胞异常增殖的恶性疾病，在很多国家是血液系统第2位常见恶性肿瘤，多发于老年，目前仍无法治愈。随着新药不断问世及检测手段的提高，MM的诊断和治疗得以不断改进和完善。本次指南在诊断部分检查项目进行了更新；危险分层部分提出了超高危MM的定义；对于大于等于二线复发患者治疗增加了包含嵌合抗原受体T细胞疗法及双特异性抗体等方案的推荐；根据现有的最佳证据治疗建议以不同级别作为推荐。

多发性骨髓瘤;指南;诊断;治疗
ABSTRACT

Multiple myeloma (MM), an incurable clonal plasma cell dysplasia, is the second most common hematological malignancy in many countries, mainly developing in the elderly population. With the emergence of novel agents and laboratory methods, the diagnosis and treatment of MM have been significantly improved. In this version of the "Guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)", several examination items have been updated in the diagnostic section; the definition of ultra high-risk MM has been proposed in the risk stratification section; for patients with equal or more than second-line relapse, chimeric antigen receptor T cell therapy and a bispecific T-cell engager have been added; and the treatment recommendations have been listed at different levels based on the best available evidence.

Multiple myeloma;Guidelines;Diagnosis;Treatment
Huang Xiaojun, Peking University People′s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China, Email: nc.defudabe.umjbnujoaixgnauh
Wu Depei, the First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China, Email: nc.defudabe.adusiepeduw
Copyright by Chinese Medical Association
No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission.
All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.
引用本文

中国医师协会血液科医师分会,中华医学会血液学分会. 中国多发性骨髓瘤诊治指南（2024年修订）[J]. 中华内科杂志,2024,63(12)：1186-1195.

DOI:10.3760/cma.j.cn112138-20240928-00616

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价
本文评分
4.33分 [累计3个]

版权归中华医学会所有。

未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。

除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。

多发性骨髓瘤（multiple myeloma，MM）是一种克隆浆细胞异常增殖的恶性疾病，在很多国家是血液系统第2位常见恶性肿瘤 ［ 1 , 2 ］ ，多发于老年，目前仍无法治愈。随着新药不断问世及检测手段的提高，MM的诊断和治疗得以不断提升。中国MM诊治指南每2~3年更新1次，这对于提高我国MM的诊治水平具有重要意义。
试读结束，您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
Wang S , Xu L , Feng J ,et al. Prevalence and incidence of multiple myeloma in urban area in China: a national population-based analysis [J]. Front Oncol, 2019,9:1513. DOI: 10.3389/fonc.2019.01513 .
返回引文位置Google Scholar
百度学术
万方数据
[2]
Liu W , Liu J , Song Y ,et al. Mortality of lymphoma and myeloma in China, 2004-2017: an observational study[J]. J Hematol Oncol, 2019,12(1):22. DOI: 10.1186/s13045-019-0706-9 .
返回引文位置Google Scholar
百度学术
万方数据
[3]
Lu J , Lu J , Chen W ,et al. Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis[J]. Blood Cancer J, 2014,4(8):e239. DOI: 10.1038/bcj.2014.55 .
返回引文位置Google Scholar
百度学术
万方数据
[4]
中华医学会血液学分会浆细胞疾病学组,中华医学会血液学分会实验诊断学组. 外周血循环浆细胞流式细胞术检测在浆细胞病中的应用中国专家共识(2024年版)[J]. 中华血液学杂志, 2024,45(4):313-321. DOI: 10.3760/cma.j.cn121090-20240117-00026 .
返回引文位置Google Scholar
百度学术
万方数据
[5]
Jin X , Li H , Zhang D ,et al. Myc rearrangement redefines the stratification of high-risk multiple myeloma[J]. Cancer Med, 2024,13(11):e7194. DOI: 10.1002/cam4.7194 .
返回引文位置Google Scholar
百度学术
万方数据
[6]
中华医学会血液学分会浆细胞疾病学组,中华医学会血液学分会血栓与止血学组. 多发性骨髓瘤相关静脉血栓栓塞症防治中国专家共识(2022年版)[J]. 中华血液学杂志, 2022,43(9):726-731. DOI: 10.3760/cma.j.issn.0253-2727.2022.09.003 .
返回引文位置Google Scholar
百度学术
万方数据
[7]
Rajkumar SV , Dimopoulos MA , Palumbo A ,et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma[J]. Lancet Oncol, 2014,15(12):e538-e548. DOI: 10.1016/S1470-2045(14)70442-5 .
返回引文位置Google Scholar
百度学术
万方数据
[8]
Mateos MV , Kumar S , Dimopoulos MA ,et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)[J]. Blood Cancer J, 2020,10(10):102. DOI: 10.1038/s41408-020-00366-3 .
返回引文位置Google Scholar
百度学术
万方数据
[9]
Durie BG , Salmon SE . A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival[J]. Cancer, 1975,36(3):842-854. DOI: 10.1002/1097-0142(197509)36∶3<842::aid-cncr2820360303>3.0.co;2-u .
返回引文位置Google Scholar
百度学术
万方数据
[10]
Greipp PR , San Miguel J , Durie BG ,et al. International staging system for multiple myeloma[J]. J Clin Oncol, 2005,23(15):3412-3420. DOI: 10.1200/JCO.2005.04.242 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
Palumbo A , Avet-Loiseau H , Oliva S ,et al. Revisedinternational staging system for multiple myeloma: a report from International Myeloma Working Group[J]. J Clin Oncol, 2015,33(26):2863-2869. DOI: 10.1200/JCO.2015.61.2267 .
返回引文位置Google Scholar
百度学术
万方数据
[12]
D′Agostino M , Cairns DA , Lahuerta JJ ,et al. Second Revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: A European Myeloma Network (EMN) report within the HARMONY project[J]. J Clin Oncol, 2022,40(29):3406-3418. DOI: 10.1200/JCO.21.02614 .
返回引文位置Google Scholar
百度学术
万方数据
[13]
Walker BA , Mavrommatis K , Wardell CP ,et al. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis[J]. Leukemia, 2019,33(1):159-170. DOI: 10.1038/s41375-018-0196-8 .
返回引文位置Google Scholar
百度学术
万方数据
[14]
Baysal M , Demirci U , Umit E ,et al. Concepts of double hit and triple hit disease in multiple myeloma, entity and prognostic significance[J]. Sci Rep, 2020,10(1):5991. DOI: 10.1038/s41598-020-62885-0 .
返回引文位置Google Scholar
百度学术
万方数据
[15]
Jelinek T , Bezdekova R , Zihala D ,et al. More than 2% of circulating tumor plasma cells defines plasma cell leukemia-like multiple myeloma [J]. J Clin Oncol, 2023,41(7):1383-1392. DOI: 10.1200/JCO.22.01226 .
返回引文位置Google Scholar
百度学术
万方数据
[16]
Bertamini L , Oliva S , Rota-Scalabrini D ,et al. High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma[J]. J Clin Oncol, 2022,40(27):3120-3131. DOI: 10.1200/JCO.21.01393 .
返回引文位置Google Scholar
百度学术
万方数据
[17]
Yan W , Xu J , Fan H ,et al. Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma[J]. Cancer, 2024,130(3):421-432. DOI: 10.1002/cncr.35056 .
返回引文位置Google Scholar
百度学术
万方数据
[18]
Corre J , Montes L , Martin E ,et al. Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk[J]. Haematologica, 2020,105(9):e480-e483. DOI: 10.3324/haematol.2019.236588 .
返回引文位置Google Scholar
百度学术
万方数据
[19]
Kumar S , Paiva B , Anderson KC ,et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma[J]. Lancet Oncol, 2016,17(8):e328-e346. DOI: 10.1016/S1470-2045(16)30206-6 .
返回引文位置Google Scholar
百度学术
万方数据
[20]
Sun Q , Li X , Gu J ,et al. Prognostic significance of the stage at which an MRD-negative status is achieved for patients with multiple myeloma who received ASCT[J]. Front Oncol, 2022,12:776920. DOI: 10.3389/fonc.2022.776920 .
返回引文位置Google Scholar
百度学术
万方数据
[21]
中华医学会血液学分会实验诊断学组、浆细胞疾病学组,中国医师协会多发性骨髓瘤专业委员会. 基于骨髓样本的多发性骨髓瘤微小残留病检测中国专家共识(2024年版)[J]. 中华血液学杂志, 2024,45(6):534-541. DOI: 10.3760/cma.j.cn121090-20240430-00167 .
返回引文位置Google Scholar
百度学术
万方数据
[22]
Jian Y , Chang L , Shi MX ,et al. Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment[J]. Blood Adv, 2023,7(24):7581-7584. DOI: 10.1182/bloodadvances.2023011428 .
返回引文位置Google Scholar
百度学术
万方数据
[23]
Rifkin RM , Girnius SK , Noga SJ ,et al. In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management[J]. Blood Cancer J, 2023,13(1):147. DOI: 10.1038/s41408-023-00912-9 .
返回引文位置Google Scholar
百度学术
万方数据
[24]
Liu A , Yu H , Hou R ,et al. Assessment of prolonged proteasome inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort study[J]. Cancer Med, 2024,13(9):e7177. DOI: 10.1002/cam4.7177 .
返回引文位置Google Scholar
百度学术
万方数据
[25]
Mina R , Musto P , Rota-Scalabrini D ,et al. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial[J]. Lancet Oncol, 2023,24(1):64-76. DOI: 10.1016/S1470-2045(22)00693-3 .
返回引文位置Google Scholar
百度学术
万方数据
[26]
Xia Z , Leng Y , Fang B ,et al. Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial[J]. BMC Cancer, 2023,23(1):980. DOI: 10.1186/s12885-023-11489-8 .
返回引文位置Google Scholar
百度学术
万方数据
[27]
Li C , Wang D , Song Y ,et al. CT103A, a novel fully human BCMA-targeting CAR-T cells, in patients with relapsed/refractory multiple myeloma: updated results of phase 1b/2 study (FUMANBA-1)[J]. J Clin Oncol, 2023,41(16):Suppl. 8025DOI: 10.1200/JCO.2023.41.16_suppl.8025 .
返回引文位置Google Scholar
百度学术
万方数据
[28]
Chen W , Fu C , Fang B ,et al. Phase Ⅱ study of fully human BCMA- targeting CAR-T cells (zevorcabtagene autoleucel) in patients with relapsed/refractory multiple myeloma [J]. Blood, 2022,140(Suppl 1):4564-4565. DOI: 10.1182/blood-2022-168610 .
返回引文位置Google Scholar
百度学术
万方数据
[29]
Mi JQ , Zhao W , Jing H ,et al. Phase Ⅱ, open-label study of ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor-T-cell therapy, in Chinese patients with relapsed/refractory multiple myeloma (CARTIFAN-1)[J]. J Clin Oncol, 2023,41(6):1275-1284. DOI: 10.1200/JCO.22.00690 .
返回引文位置Google Scholar
百度学术
万方数据
[30]
Moreau P , Garfall AL , van de Donk N ,et al. Teclistamab in relapsed or refractory multiple myeloma[J]. N Engl J Med, 2022,387(6):495-505. DOI: 10.1056/NEJMoa2203478 .
返回引文位置Google Scholar
百度学术
万方数据
[31]
中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2022年版)[J]. 肿瘤综合治疗电子杂志, 2022,8(2):16-53. DOI: 10.12151/JMCM.2022.02-04 .
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
黄晓军，北京大学人民医院 北京大学血液病研究所 国家血液系统疾病临床医学研究中心，北京 100044，Email： nc.defudabe.umjbnujoaixgnauh
B
吴德沛，苏州大学附属第一医院 江苏省血液研究所 国家血液系统疾病临床医学研究中心，苏州 215006，Email： nc.defudabe.adusiepeduw
C
中国医师协会血液科医师分会, 中华医学会血液学分会. 中国多发性骨髓瘤诊治指南（2024年修订）[J]. 中华内科杂志, 2024, 63(12): 1186-1195. DOI: 10.3760/cma.j.cn112138-20240928-00616.
D
所有作者声明无利益冲突
评论 （0条）
注册
登录
时间排序
暂无评论，发表第一条评论抢沙发
最新推荐
更多
多发性骨髓瘤肾损伤诊治指南（2024版）
中国医师协会血液科医师分会 等
中华内科杂志 2024,63(04)
中国药物性肝损伤诊治指南（2023年版）
中国医药生物技术协会药物性肝损伤防治技术专业委员会 等
中华肝脏病杂志 2023,31(04)
中国多发性骨髓瘤诊治指南（2022年修订）
中国医师协会血液科医师分会 等
中华内科杂志 2022,61(05)
中国多发性骨髓瘤诊治指南（2020年修订）
中国医师协会血液科医师分会 等
中华内科杂志 2020,59(05)
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照

你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持：

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大